News

OneSource Q1 FY27: Semaglutide Has Turned a Bengaluru CDMO Into a 37% Revenue-Growth Story — With Biologics Next

By Mustafa Shariff, Editor in Chief · July 27 ,2026 · 2 mins read

Mustafa Shariff, Editor in Chief — OneSource Q1 FY27: Semaglutide Has Turned a Bengaluru CDMO Into a 37% Revenue-Growth Story — With Biologics Next

Summary

  • OneSource Q1 FY27: 37% Revenue Growth as Semaglutide Launches Drive Bengaluru CDMO's Commercial Breakthrough
  • OneSource Specialty Pharma reported Q1 FY27 revenue of ₹449 crore (+37% YoY), EBITDA ₹123.3 crore (+39%), EBITDA margin 27.5% — driven by semaglutide commercial launches in Canada and India, Formycon biosimilar partnership, and new MSA contracts.

"Q1 FY27 marks our transition from pre-approval activities to full commercial CDMO execution. The semaglutide launches in Canada and India have validated our manufacturing capability at regulated market standard. With a second cartridge line coming in Q2, a biosimilar partnership with Formycon, and our FY28 guidance of $400 million organic revenue at 40% EBITDA margin, we are tracking exactly to plan. This is what we said we would build. This is what it looks like."

OneSource Specialty Pharma Limited, the Bengaluru-headquartered contract development and manufacturing organisation listed on NSE and BSE, reported its consolidated financial results for the first quarter ended June 30, 2026 — the quarter that marks the company's transition from a pre-commercial CDMO story to a commercially validated, revenue-generating platform.
Consolidated revenue from operations reached ₹4,490 million (₹449 crore, $47.5 million) for Q1 FY27, representing 37% year-on-year growth and 5% sequential growth from Q4 FY26. EBITDA reached ₹1,233 million (₹123.3 crore, $13.1 million), up 39% year-on-year and 34% sequentially, with EBITDA margins expanding to 27.5% — a 600 basis point improvement quarter-on-quarter and a 43 basis point improvement year-on-year. Net profit on a standalone basis reached ₹512 million, up from ₹248 million in the prior year period.
Semaglutide: From Approval to Commercial Revenue
The commercial launch of semaglutide — the GLP-1 receptor agonist whose Indian compound patent expired on March 20, 2026 — is the central driver of Q1 FY27's revenue and margin performance. BHC Media has tracked the OneSource semaglutide story closely throughout 2026: the company's US FDA-approved Bengaluru facility received Health Canada approval for Dr Reddy's generic semaglutide (covered July 1 edition), and now the commercial volume from those and Indian market launches is flowing through OneSource's financial statements at scale.
OneSource is supplying semaglutide to a significant portion of India's generic pen brands — a market that Pharmarack data reported crossed ₹2,055 crore in June 2026 — alongside the Health Canada-approved Canadian supply to Dr Reddy's. The simultaneous launch across two regulated markets (India and Canada) in a single quarter has generated the operating leverage that pushed EBITDA margins from below 20% in earlier quarters to the 27.5% level that Q1 FY27 demonstrates.
Beyond Semaglutide: New MSA Contracts and Customer Wins
While semaglutide commercialisation is the headline driver, OneSource's Q1 FY27 growth also reflects the execution of new Master Services Agreement contracts and customer additions across its business units — the structural commercial momentum that underpins the company's FY28 guidance rather than relying on a single product's market share.
Critically, OneSource confirmed on July 9, 2026 that its operations remain unhindered by external semaglutide supply chain delays — directly relevant given the broader global semaglutide supply constraints that have affected some manufacturers, and a signal that OneSource's Bengaluru manufacturing infrastructure is operating with sufficient supply chain resilience to maintain commercial commitments.
Biologics: The Formycon Partnership
On July 14, 2026, OneSource announced a strategic biosimilar manufacturing partnership with Formycon AG — a Munich-based biosimilar developer with an established portfolio of ophthalmic and other biosimilar programmes. The Formycon partnership represents OneSource's clearest signal yet of its intent to extend the GLP-1 peptide CDMO franchise into biologics manufacturing — a strategically important diversification given that peptide GLP-1 generics, while currently high-growth, will face increasing competition from more CDMOs building peptide capacity.
Capacity and FY28 Guidance
OneSource is progressing with the commercialisation of a second cartridge line in Q2 FY27, expected to support further volume growth in semaglutide and other injectable pen products. The company reaffirmed its FY28 guidance of $400 million in organic revenue with a 40% steady-state EBITDA margin — implying approximately 8-9x Q1 FY27's annualised revenue run rate of approximately $190 million, requiring significant additional business development and capacity deployment over the next six quarters.
BHC Perspective
At Bengaluru Health Community, OneSource's Q1 FY27 results are the financial proof of concept for the Bengaluru pharmaceutical manufacturing story that BHC Media has been documenting throughout 2026. A Bengaluru CDMO that built regulatory-quality peptide manufacturing infrastructure is now generating 37% revenue growth and 27.5% EBITDA margins from commercial GLP-1 supply to Canada and India simultaneously. For BHC founders in pharmaceutical CDMO, peptide manufacturing, or biologics development — OneSource is the local proof point that the business model works.
Frequently Asked Questions
Q: What were OneSource's Q1 FY27 results?
A: Consolidated revenue ₹449 crore ($47.5M), +37% YoY. EBITDA ₹123.3 crore ($13.1M), +39% YoY. EBITDA margin 27.5%, +600 bps QoQ. Standalone net profit ₹512M vs ₹248M in prior year. Driven by semaglutide commercial launches in Canada and India, new MSA contracts, and customer wins.
Q: What is the Formycon partnership?
A: A strategic biosimilar manufacturing partnership announced July 14, 2026, with Formycon AG — a Munich-based biosimilar developer. Represents OneSource's move to extend its GLP-1 peptide CDMO franchise into biologics manufacturing.
Q: What is OneSource's FY28 guidance?
A: $400 million in organic revenue with 40% steady-state EBITDA margin, reaffirmed after Q1 FY27 results. The company is also commissioning a second cartridge line in Q2 FY27 to support further volume growth.